Continuous administration of epitopes derived from protein...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/00 (2006.01) A61K 9/70 (2006.01) A61P 9/10 (2006.01)

Patent

CA 2594363

The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.

La présente invention concerne une composition ou un timbre prévu pour le traitement prophylactique ou thérapeutique au moyen de l'administration continue par voie sous-cutanée, d'un patient souffrant d'athérosclérose. Cette composition ou ce timbre comprend une quantité efficace d'au moins un épitope dérivé d'une protéine présente dans la plaque d'athérosclérose, l'administration dudit épitope audit sujet induisant une réponse immunitaire régulatoire spécifique, de préférence la réponse Treg.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Continuous administration of epitopes derived from protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Continuous administration of epitopes derived from protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Continuous administration of epitopes derived from protein... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1779274

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.